Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing

Launched by GOOD SAMARITAN HOSPITAL MEDICAL CENTER, NEW YORK · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective two specific tests, OncoTarget and OncoTreat, can be in helping patients with oligometastatic disease, which means they have a limited number of cancer spots in their body. The goal is to see if these tests can guide doctors in choosing the best treatment options for patients who are already receiving radiation therapy. The study will involve 20 patients who will provide a small sample of their tumor before the testing takes place. The results from these tests may help improve treatment outcomes for patients who have had poor results with standard therapies.

To be eligible for the trial, participants must be at least 18 years old and have a specific type of cancer that has spread but can be treated with radiation. Patients with brain metastases can join as long as they have no more than 10 spots and can receive radiation to all affected areas. Those who qualify will go through the testing process and may receive treatment based on what the tests suggest. It’s important to note that this study is not yet recruiting participants, and there are specific health conditions that may exclude some patients from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age ≥18 years with metastatic solid tumor who are candidates for comprehensive involved site radiotherapy to all areas of disease seen on whole body imaging.
• • Patients with brain metastases are eligible provided they qualify as oligometastases (up to 10 lesions based on the SABR-COMET-10 trial) and are treatable with radiotherapy to all areas of visible disease.
• • Patients with adequate bone marrow (absolute neutrophil ≥1000, hemoglobin ≥ 9 g/dl, platelets ≥100,000), kidney (creatinine ≤1.5 times upper limit of normal) and liver (bilirubin ≤1.5 times upper limit of normal).
• • Patients being treated by radiation oncology at Good Samaritan University Hospital.
• Exclusion Criteria:
• • Patients with an estimated median survival of less than 6 months using the published and validated NEAT methodology.
• • Patients who are pregnant and/or breast feeding or those with severe uncontrolled cardiac, pulmonary, infectious or organic brain disease.